#elahere

[jbgranic]

https://www.nasdaq.com/articles/european-commission-approves-abbvies-elahere-platinum-resistant-ovarian-cancer-treatment

European Commission Approves AbbVie's ELAHERE For Platinum-Resistant Ovarian Cancer Treatment

[biotech-news-feed]

SEP 20, 2024 | 4:30 PM PDT | BIOCENTURY | DATA BYTEABBVIE’S ELAHERE GETS CHMP NOD AS COMPETITION ADVANCESBY Plus: Roche withdraws an application for Tecentriq combo, and AbbVie for Durysta https://www.biocentury.com/article/653628/abbvie-s-elahere-g #BioTech #science

[biotechtv]

Mark Enyedy discusses how the launch of the antibody-drug conjugate Elahere in platinum resistant ovarian cancer is progressing.

[amcrasto]

Mirvetuximab soravtansine-gynx

Mirvetuximab soravtansine-gynx FDA 11/14/2022, To treat patients with rTo treat patients with recurrent ovarian cancer that is resistant to platinum therapy that is resistant to platinum therapy,  Elahere FDA Approves Mirvetuximab Soravtansine-gynx for FRα+ Platinum-resistant Ovarian Cancer https://www.biochempeg.com/article/315.html 4846-85a8-48171ab38275 FDA Approves Mirvetuximab…

[biotech-news-feed]

APR 26, 2024 | 5:10 PM PDT | BIOCENTURY | DATA BYTEFDA LABEL EXPANSIONS: MARCH BROUGHT FULL APPROVALS OF ELAHERE, RYBREVANTBY Plus: Approvals in earlier cancer lines for Rybrevant and Opdivo, and new indications for four more productshttps://www.bio #BioTech #science

[biotechtv]

Discussing the MIRASOL ovarian cancer data with Immunogen at #ASCO23.